Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure

[1]  Francis G Spinale,et al.  Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. , 2006, Journal of cardiac failure.

[2]  Anne M Deschamps,et al.  Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. , 2006, Cardiovascular research.

[3]  G. Keren,et al.  Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. , 2005, American heart journal.

[4]  J. Kaski,et al.  N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. , 2005, The American journal of cardiology.

[5]  F. Veglia,et al.  Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. , 2005, European heart journal.

[6]  A. Yan,et al.  Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials , 2005, Annals of Internal Medicine.

[7]  Leong L Ng,et al.  Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. , 2004, Journal of cardiac failure.

[8]  G. Baxter.  The natriuretic peptides , 2004, Basic Research in Cardiology.

[9]  T. Ueda,et al.  Circulating matrix metalloproteinase‐2 is elevated in patients with congestive heart failure , 2003, European journal of heart failure.

[10]  J. Higaki,et al.  Serum levels of matrix metalloproteinases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. , 2003, The American journal of cardiology.

[11]  J. Burnett,et al.  Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases , 2002, Circulation research.

[12]  Sidney Goldstein,et al.  Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure , 2002, Circulation.

[13]  Anita Deswal,et al.  Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. , 2002, Journal of cardiac failure.

[14]  F. Spinale,et al.  Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. , 2001, American journal of physiology. Heart and circulatory physiology.

[15]  F. Spinale,et al.  Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure , 2001, Circulation.

[16]  R. McKelvie,et al.  Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. , 2000, Circulation.

[17]  S. Yusuf,et al.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.

[18]  M. Zile,et al.  Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. , 1999, Circulation research.

[19]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[20]  F. Spinale,et al.  Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. , 1998, Circulation.

[21]  T. Ueno,et al.  Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. , 1998, Journal of the American College of Cardiology.

[22]  S. Yusuf,et al.  Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. , 1997, The Canadian journal of cardiology.

[23]  F. Spinale.  Matrix Metalloproteinases Regulation and Dysregulation in the Failing Heart , 2002 .